ClinicalTrials.gg
CompletedNCT00971841Updated Jul 26, 2013Results posted

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer

A Phase 2 interventional study of Paclitaxel in Esophageal Cancer, sponsored by Bristol-Myers Squibb. Completed. Per ClinicalTrials.gov, last updated 2013-07-26.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing paclitaxel in Esophageal Neoplasms — 11 open to participants now, 18 under way, none of them phase 3. Paclitaxel · Esophageal Neoplasms.

Enrollment
70th of 74
1 · median 40
Started
2008
with 5 others
Phase 2
48 of 80
6 open now
Registered
34th of 80
by date
Lead sponsor
2 of 80
Bristol-Myers Squibb

Among the 80 studies testing paclitaxel in Esophageal Neoplasms, this one is the 70th largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2008, is one of 48 in phase 2, and was the 34th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

11 of the 80 studies testing paclitaxel in Esophageal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing paclitaxel in Esophageal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced or recurrent esophageal cancer who have completed the previous Phase 2 study (CA139-540) and who should continue on therapy with paclitaxel as assessed by the treating investigator(s). To evaluate the severity of observed adverse reactions in treated subjects for assessment of long-term safety.

03

Conditions studied

  • Esophageal Cancer
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subjects with advanced or recurrent esophageal cancer who have completed the previous late Phase 2 study (CA139-540) and for who continued therapy with paclitaxel would be beneficial as deemed by the investigator(s).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Paclitaxel

    One hour intravenous infusion on Days 1, 8, 15, 22, 29, 36, followed by 1 week of rest (6 weeks on, 1 week off). One treatment course consists of 49 days. Day 1 dose same level as last dose of original Study CA139-540 (100mg/m2, 80 mg/m2, or 60 mg/m2). Treatment to continue until disease progression or unacceptable toxicity apparent.

    Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events (AEs) Per Participant

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Severity of the adverse event was judged and graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0.

    Time frame: Weekly Day 1 to 4 years

Secondary outcomes

  1. Number of Participants With Complete Response to Tumor

    Tumor measured/evaluated via imaging and assessed according to the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.0 wherein complete response is disappearance of all target lesions; partial response is 30% decrease in the sum of the longest diameter of target lesions; progressive disease is 20% increase in the sum of the longest diameter of target lesions, and stable disease is small changes that do not meet above criteria. The baseline assessment was done prior to the first administration of drug in the original Study CA139-540 (NCT 00344552).

    Time frame: Every 7 weeks Day 1 to 4 years

07

Results

Posted Jul 19, 2013
Limitations and caveats
Upon completion of Study CA139-540 (NCT 00344552), one subject (who had received 7 courses paclitaxel) rolled over into Study CA139-557. During four years in Study CA139-557, subject received an additional 30 courses of paclitaxel.

Participant flow

Original Study CA139-540 (NCT 00344552) at Dr. K. Kato National Cancer Center Hospital in Tokyo, Japan, closed in 2008 and one participant rolled over into Study CA139-557.

Participant flow — Overall Study
MilestonePaclitaxel
Started1
Completed1
Not completed0

Outcome measures

PrimaryNumber of Adverse Events (AEs) Per Participant

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Severity of the adverse event was judged and graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0.

Time frame:
Weekly Day 1 to 4 years
Reported as:
Number · adverse events
Number of Adverse Events (AEs) Per Participant
adverse eventsPaclitaxel
Number of Adverse Events (AEs) Per Participant32
SecondaryNumber of Participants With Complete Response to Tumor

Tumor measured/evaluated via imaging and assessed according to the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.0 wherein complete response is disappearance of all target lesions; partial response is 30% decrease in the sum of the longest diameter of target lesions; progressive disease is 20% increase in the sum of the longest diameter of target lesions, and stable disease is small changes that do not meet above criteria. The baseline assessment was done prior to the first administration of drug in the original Study CA139-540 (NCT 00344552).

Time frame:
Every 7 weeks Day 1 to 4 years
Reported as:
Number · participants
Number of Participants With Complete Response to Tumor
participantsPaclitaxel
Number of Participants With Complete Response to Tumor1

Adverse events

Collected over 4 years (4 March 2008 to 24 March 2012). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paclitaxel—0/1 (0%)1/1 (100%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPaclitaxel
neutrophil count decreaseInvestigations1/1
alopeciaSkin and subcutaneous tissue disorders1/1
back painMusculoskeletal and connective tissue disorders1/1
blood pressure increasedInvestigations1/1
chillsGeneral disorders1/1
contusionInjury, poisoning and procedural complications1/1
coughRespiratory, thoracic and mediastinal disorders1/1
cystitisInfections and infestations1/1
decreased appetiteMetabolism and nutrition disorders1/1
dizzinessNervous system disorders1/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Paclitaxel
<=18 years0
Between 18 and 65 years1
>=65 years0
Age Continuous
Age Continuous(years)Paclitaxel
Mean47 ± NA
Sex: Female, Male
Sex: Female, Male(Participants)Paclitaxel
Female1
Male0
Region of Enrollment
Region of Enrollment(participants)Paclitaxel
Japan1
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2009
First posted
Sep 4, 2009
Start
Mar 2008
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
Jul 19, 2013
Last update
Jul 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00971841
Responsible party
Sponsor
First posted
Sep 4, 2009
Start date
Mar 2008
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Jul 19, 2013
Last update
Jul 26, 2013

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion